Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.
about
Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteersNitric oxide synthase derangements and hypertension in kidney diseaseStatins as regulators of redox state in the vascular endothelium: beyond lipid loweringAutoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunityTargeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of HypertensionAsymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicabilityInterplay between Oxidative Stress and Nutrient Sensing Signaling in the Developmental Origins of Cardiovascular Disease.Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD)Endothelial dysfunction in chronic inflammatory diseasesRestoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension.Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertensionPlasma levels of dimethylarginines in preterm very low birth weight neonates: its relation with perinatal factors and short-term outcome.Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring CohortArginine and asymmetric dimethylarginine in pregnant women with major depressionLeft ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertensionPreventing a Cardiovascular Disease Epidemic among Indigenous Populations through Lifestyle Changes.Arginines Plasma Concentration and Oxidative Stress in Mild to Moderate COPD.Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis.Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective StudiesSymmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.Cellular interactions between L-arginine and asymmetric dimethylarginine: Transport and metabolism.Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.Omega-3 Status and the Relationship between Plasma Asymmetric Dimethylarginine and Risk of Myocardial Infarction in Patients with Suspected Coronary Artery Disease.Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.Asymmetric dimethylarginine predicts survival in the elderlyDifferential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.Cellular ADMA: regulation and action.A click chemistry mediated in vivo activity probe for dimethylarginine dimethylaminohydrolase.Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency.Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.Nitric Oxide Synthase Inhibitors as Antidepressants.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.L-Arginine and its metabolites in kidney and cardiovascular disease.A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.Clinical Significance of Endothelial Dysfunction in Essential Hypertension.Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2.Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm.Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS.
P2860
Q24338511-5787C703-7565-48CC-8A92-ED5431C321BEQ26849234-DA457C87-F97B-4FB0-BD50-EFB4B49DB9A9Q26853120-7AFB7084-53E8-4C11-80AC-D0F97FB1F5D5Q27004493-9D2036F5-5AD5-4519-88F9-5F0EC4B89900Q28069733-4C9573F4-85D9-4516-93BF-E56E0A6D4FC0Q28075206-F34DEC4B-2D44-443C-873D-E27FF4E69BD1Q28081407-32F77187-22FD-4D28-ACD8-EB2CFB7309DAQ30234757-89574595-52D1-4BE7-855F-C79C494ACFA2Q33580586-1D7239E6-D405-4779-94FB-4A870842021AQ34072179-CC7B256B-69F6-46B3-916B-A675B2598DF7Q34072296-D852732B-7535-479B-9421-74F9B46BEEF5Q34460993-183DB879-8651-4F16-A2CE-7A3E8CCA688AQ35016382-9CC200A1-3C2F-47F2-88D9-7D6D77520460Q35572566-C72CC75F-7E67-4CDD-89C1-4B3A72F71FC3Q35787031-12CB7072-8349-49F0-9047-921E9293FBF9Q35829220-FF3B92D9-43E6-44E0-89AD-337E507E5386Q35966335-D9D23E6A-DD9C-4A92-84B1-A17F7E817D34Q36091725-1633AAFC-A9C7-4F8B-9B03-4ACCC08D48ADQ36167351-59F4B261-1318-4A77-824F-0657C0E0B339Q36182184-3A39BC44-4560-422A-AE68-7AD345903F2DQ36205262-C52DF105-AE78-455B-B432-52E2E83D08AEQ36386405-DCA142CE-C2A9-4821-B285-5E51397D5A24Q36396428-A61242E9-BE56-4288-9527-E72CDB461FD9Q36546557-660306E5-B07D-4294-B0CE-9542E799C8FDQ36701882-9FF1FF4B-D8BD-4AA0-B168-7AED365F7A30Q36811699-3730E7EB-5D6E-4E26-818C-9C21DE87B771Q37300523-ACD6A4DD-5F21-4968-A1DE-F2AD78EA5D8EQ37365823-5E9F7E08-55D9-4E74-98FC-4FA14A7062FCQ37399711-EB503652-4256-41A2-9B64-FFEC9D1D0D22Q37435352-04654BCC-2E9B-4559-85FC-69DD7AA7AD69Q37702780-6E178776-6FE9-4761-9139-3CF00CDF4D49Q37704715-15C88C53-6E31-47EF-8BB8-564DF3BE3C5CQ37709458-76932237-954D-4CE7-BD49-599505D65A78Q38203518-5206D2EB-0EC8-4391-B79A-EA0EBEBAF56CQ38243758-2982CD2A-7543-4556-B0D9-A4CFB8B64921Q38477549-286631D9-E207-4A78-ADB3-F0E5952C97E6Q38586940-244DFEB0-01FA-4CFF-AD08-713025CC7B78Q38832760-839FB910-3173-4553-9A88-83A59F831E38Q39247550-595722AC-5639-4B8B-8F3E-989636100249Q39600092-8BFF67C1-AA4D-4A3E-8A9A-56524ADB0BB7
P2860
Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Asymmetric dimethylarginine (A ...... range of cardiovascular risk.
@en
type
label
Asymmetric dimethylarginine (A ...... range of cardiovascular risk.
@en
prefLabel
Asymmetric dimethylarginine (A ...... range of cardiovascular risk.
@en
P2093
P1476
Asymmetric dimethylarginine (A ...... range of cardiovascular risk.
@en
P2093
Edzard Schwedhelm
Friedrich Schulze
Rainer H Böger
Renke Maas
P304
P356
10.1016/J.PHRS.2009.07.001
P577
2009-07-22T00:00:00Z